Clinical Reasoning · Article 12

Which Patients With MASLD Need Fibrosis Assessment?

MASLD evaluation requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

MASLD evaluation clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

MASLD evaluation: practical clinical approach

This page focuses on MASLD evaluation with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for MASLD evaluation

Clinical takeaway: For MASLD evaluation, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer in brief: Fibrosis assessment is appropriate when MASLD is suspected because fibrosis—not steatosis alone—drives most liver-related outcomes. Patients with hepatic steatosis on imaging, unexplained aminotransferase elevation or metabolic risk factors that create substantial MASLD risk should undergo a simple first-line fibrosis assessment. FIB-4 is the best-validated low-cost starting point. A value below 1.3 generally identifies low risk in adults aged 35-65; a value at or above 1.3 should prompt secondary assessment, commonly vibration-controlled transient elastography. Age modifies interpretation, particularly above 65 years.

Who should enter the pathway?

The pathway is especially relevant for people with type 2 diabetes, obesity with additional metabolic risk factors, incidentally noted steatosis, or persistent unexplained aminotransferase elevation. Repeated normal ALT values do not exclude fibrosis, particularly in diabetes and obesity.

Why FIB-4 comes first

FIB-4 uses age, AST, ALT and platelet count. It is not a diagnostic test for MASH, but it performs well as a rule-out tool for advanced fibrosis. AASLD materials commonly use <1.3 as a low-risk threshold in adults aged 35-65. Patients with type 2 diabetes or multiple metabolic risk factors should be reassessed more frequently than metabolically lower-risk patients.

When FIB-4 is not low

A FIB-4 of 1.3 or greater should generally lead to a secondary test rather than immediate biopsy. VCTE is widely available and practical; ELF is another validated option, while MR elastography offers high accuracy when results are discordant or the clinical stakes are high. A FIB-4 above approximately 2.67 substantially increases concern for advanced fibrosis.

Age matters

FIB-4 can overclassify older adults because age is part of the equation and can underperform in younger adults. AASLD educational guidance uses an age-adjusted lower-risk threshold around 2.0 in those older than 65 and recommends alternative assessment when a younger patient has meaningful clinical risk despite a low FIB-4.

Repeat testing is part of care

A low-risk result is not a lifetime clearance. Metabolic disease changes over time. People with diabetes or multiple metabolic risk factors typically warrant repeat assessment every 1-2 years; lower-risk patients can often be reassessed less frequently.

A practical clinical approach

Identify patients with steatosis, metabolic risk or unexplained aminotransferase elevation.
Calculate FIB-4 unless age/clinical context makes it unreliable.
If clearly low risk, manage metabolic disease and repeat risk assessment at an appropriate interval.
If FIB-4 is indeterminate/high, obtain VCTE, ELF or another validated secondary assessment.
Refer patients with high-risk or discordant results, suspected advanced fibrosis or cirrhosis, or diagnostic uncertainty.

Common errors to avoid

Using ALT alone to decide who has significant liver disease.
Sending every intermediate FIB-4 directly to biopsy.
Ignoring the age effect on FIB-4.
Failing to repeat fibrosis assessment as diabetes, weight and metabolic risk evolve.

What should trainees remember?

FIB-4 is a triage tool. Its clinical value comes from identifying who can remain in lower-intensity follow-up and who needs a second-stage fibrosis test.

Frequently asked questions

What FIB-4 is considered low risk?

For many adults aged 35-65, <1.3 is used as a low-risk threshold.

What should happen if FIB-4 is 1.3 or higher?

Use a secondary fibrosis assessment such as VCTE rather than diagnosing advanced fibrosis from FIB-4 alone.

Does a normal ALT rule out advanced fibrosis?

No.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.

2. Thomson ABR. Best Practice Guidelines in Hepatopancreaticobiliary Disorders. CAPstone Academic Publishers; 2024. ISBN 979-8861272735.

3. Rinella ME, et al. AASLD Practice Guidance. Hepatology. 2023;77:1797-1835.

4. AASLD Liver Fellow Network. Spare Me the Jab: Noninvasive Assessment of Patients with MASLD. 2023.

5. AASLD Liver Fellow Network. Why Are Non-invasive Risk Scores Such as FIB-4 Used in Clinical Practice?

← Back to Clinical Questions